These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15482785)

  • 1. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
    La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
    Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
    Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome.
    Wang JG; Nakhuda GS; Guarnaccia MM; Sauer MV; Lobo RA
    Am J Obstet Gynecol; 2007 Jan; 196(1):77.e1-5. PubMed ID: 17240243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
    Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ
    Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.
    Cook CL; Siow Y; Brenner AG; Fallat ME
    Fertil Steril; 2002 Jan; 77(1):141-6. PubMed ID: 11779604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of insulin resistance on the outcome of laparoscopic ovarian diathermy in women with polycystic ovarian syndrome.
    Amer S; Li TC; Samuelson C; Ledger W
    Acta Obstet Gynecol Scand; 2011 Apr; 90(4):338-43. PubMed ID: 21306324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma level of calcitonin gene-related peptide in patients with polycystic ovary syndrome and its relationship to hormonal and metabolic parameters.
    Zhang Z; Gong F; Lu GX
    Peptides; 2012 Apr; 34(2):343-8. PubMed ID: 22314079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome.
    Siow Y; Kives S; Hertweck P; Perlman S; Fallat ME
    Fertil Steril; 2005 Oct; 84(4):938-44. PubMed ID: 16213847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
    Chu MC; Carmina E; Wang J; Lobo RA
    Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
    Pehlivanov B; Mitkov M
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
    Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB
    Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Codner E; Maliqueo M; Echiburú B; Hitschfeld C; Crisosto N; Pérez-Bravo F; Recabarren SE; Cassorla F
    J Clin Endocrinol Metab; 2006 Aug; 91(8):3105-9. PubMed ID: 16720659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
    Ságodi L; Lombay B; Vámosi I; Barkai L
    Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.
    Yilmaz M; Ergün MA; Karakoç A; Yurtçu E; Cakir N; Arslan M
    Gynecol Endocrinol; 2006 Jun; 22(6):336-42. PubMed ID: 16785159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.